DoD Peer Reviewed Cancer Translational Team Science Award

The summary for the DoD Peer Reviewed Cancer Translational Team Science Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.
DoD Peer Reviewed Cancer Translational Team Science Award: The Translational Team Science Award supports hypothesis-driven translational studies associated with an ongoing or completed clinical trial that could lead to a next-phase clinical trial or future clinical application. By leveraging information from ongoing or completed clinical trials, research projects funded by the TTSA should address critical knowledge gaps in outcomes, validate key research and expand upon potential transformative results, or investigate novel findings. Observations from ongoing or completed clinical trials may be utilized to formulate a new hypothesis to move to the next research stage or step of implementation of the clinical outcomes. The TTSA is not intended to fund the ongoing clinical trial. Applications associated with a clinical trial not yet started are discouraged. The TTSA may support preclinical studies in animal models and human subjects and human anatomical substances. Accordingly, development or use of relevant preclinical models may be included. The TTSA is not intended to support high-throughput screenings, sequencing, etc.

Funding for clinical trials is not allowed. A clinical trial is defined as a prospective accrual of patients where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the subject of that intervention or interaction.

If a clinical trial is described in the context of the application package, it is incumbent upon the applicant to ensure that it is clear that the clinical trial associated with the proposed research will not be funded through this award mechanism.

The Translational Team Science Award mechanism requires at least two, and up to three, Principal Investigators (PIs). One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI(s) will be identified as a Partnering PI(s). Initiating and Partnering PIs each have different submission requirements, as described in Section II; however, all PIs should contribute significantly to the development of the proposed research project. If recommended for funding, each PI will receive his or her own award.

Applications should include clearly stated plans for interactions among all PIs and organizations involved. The plans must include communication, coordination of research progress and results, and data transfer. Additionally, applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award.

Important aspects of the Translational Team Science Award are as follows:

Collaboration: The success of the project depends on the unique skills and contributions of each collaborator. At least two, and up to three, PIs must partner in one overarching study in at least one of the required FY16 PRCRP Topic Areas in Section I.B. At least one military or VA investigator is encouraged to be included as an equal partner in the research offering both intellectual investment and research effort.

○ A military or VA investigator is an investigator defined as active duty, active reserve, active duty detailed to agencies outside of the DoD, etc., or an investigator at a VA research facility. The military/VA investigator should have a substantial role in the research and should not be included only for access to active duty military and/or VA populations (see ‘Military Relevance’ below).

Translational Aspect: The application should provide evidence for the reciprocal transfer of information between basic and clinical science or vice-versa in developing and implementing the research plan. Translational research should include correlative studies based on completed or ongoing clinical trials (funding for the clinical trial is not allowed) or translational research. The application should demonstrate how the study will leverage information from ongoing or completed clinical trials to address knowledge gaps in resulting outcomes, validate key research and expand upon potential transformative results, or investigate novel findings.

Military Relevance: The proposed research must address at least one of the FY16 PRCRP Military Relevance Focus Areas in Section I.C. The proposed research should be relevant to active duty Service members, their families, Veterans, and other military beneficiaries. Military relevance highlights the need to address exposures, conditions, or circumstances that are unique to the military or disproportionately represented within the military beneficiary population. Critical to the military health system is the expansion of knowledge in cancer research, patient care, and treatment options. Military relevance should be articulated with respect to the overall military health system, the VA, and the mission of the DHP. For more information, review the following websites: Military Health System (, Department of Veterans Affairs (, the PRCRP (, and the PRCRP Report to Congress (

Impact: The proposed research should have a significant impact on the concepts or methods that are likely to accelerate the movement of promising ideas (in prevention, diagnosis, detection, prognosis, treatment, and survivorship) in at least one of the FY16 PRCRP Topic Areas in Section I.B. into clinical applications.

Innovation: Research deemed innovative may represent a new paradigm, challenge existing paradigms, or look at existing problems from new perspectives. Research may be innovative in study concept, research methods or technology, or adaptations of existing methods or technologies.

Preliminary Data Required: Data from an ongoing or completed clinical trial must be included in the application and/or citations of the investigators’ work that are relevant to the proposed studies.
Federal Grant Title: DoD Peer Reviewed Cancer Translational Team Science Award
Federal Agency Name: Dept of the Army USAMRAA
Grant Categories: Science and Technology
Type of Opportunity: Discretionary
Funding Opportunity Number: W81XWH-16-PRCRP-TTSA
Type of Funding: Cooperative Agreement, Grant
CFDA Numbers: 321207
CFDA Descriptions: Military Medical Research and Development
Current Application Deadline: Sep 13, 2016
Original Application Deadline: Sep 13, 2016
Posted Date: Apr 18, 2016
Creation Date: Apr 18, 2016
Archive Date: Oct 13, 2016
Total Program Funding: $16,000,000
Maximum Federal Grant Award: none
Minimum Federal Grant Award: none
Expected Number of Awards: 10
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Grant Announcement Contact
CDMRP Help Desk Phone: 301-682-5507 Email:
CDMRP Help Desk

Dept. of the Army -- USAMRAA 301-619-7144
More Grants from the Dept of the Army USAMRAA
DoD Autism Idea Development Award
DoD Autism Clinical Translational Research Award
DoD Autism Clinical Trial Award
DoD Neurofibromatosis, Exploration- Hypothesis Development Award
DoD Neurofibromatosis, New Investigator Award is not endorsed by, or affiliated with, any government agency. Copyright ©2019